| Synonyms: | |
| Status: | Phase 2 |
| Entry Type: | Antibody |
| Molecule Category: | UNKNOWN |
| UNII: | 496K5Z02NW |
Pharmacology
| Primary Target | |
|---|---|
| integrin α5β1 | |
| integrin, alpha 5 subunit (fibronectin receptor, alpha polypeptide) |
Indications
| Mesh Heading | Maximum Phase | Mesh ID | Reference |
|---|---|---|---|
| Ovarian Neoplasms | 2 | D010051 | ClinicalTrials |
| Lung Neoplasms | 2 | D008175 | ClinicalTrials |
| Pancreatic Neoplasms | 2 | D010190 | ClinicalTrials |
| Melanoma | 2 | D008545 | ClinicalTrials |
| Peritoneal Neoplasms | 2 | D010534 | ClinicalTrials |
| Carcinoma, Non-Small-Cell Lung | 1 | D002289 | ClinicalTrials |
| Macular Degeneration | 1 | D008268 | ClinicalTrials |
Cross References
| Resources | Reference |
|---|---|
| CAS NUMBER | 558480-40-3 |
| ChEMBL | CHEMBL2108061 |
| FDA SRS | 496K5Z02NW |
| Guide to Pharmacology | 10236 |
CONTENTS